Helicobacter Pylori Antigen ELISA Kit

Produktnummer ABIN997009

Helicobacter pylori ELISA-Kit Colorimetric-Assay zur Quantifizierung von Helicobacter pylori .

Kurzübersicht für Helicobacter Pylori Antigen ELISA Kit (ABIN997009)

Target: Helicobacter Pylori Antigen

Reaktivität: Helicobacter pylori

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 0-100 ng/mL

Applikation: ELISA

Produktdetails

Untere Nachweisgrenze: 0 ng/mL

Verwendungszweck: ELISA, Helicobacter pylori Antigen is a quantitative assay for the detection of H. pylori antigens in human stool specimen.

Analytische Methode: Quantitative

Sensitivität: 0.5 ng/mL

Anwendungsinformationen

Testdauer: 1 - 2 h

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Haltbarkeit: 12-18 months

Antigendetails

Target: Helicobacter Pylori Antigen

Hintergrund: Helicobacter pylori is a spiral bacterium cultured from human gastric mucosa by Marshall in 1982. Studies have indicated that the presence of H. pylori is associated with a variety of gastrointestinal diseases including gastritis, duodenal and gastric ulcer, non-ulcer dyspepsia, gastric adenocarcinoma and lymphoma. The organism is present in 95-98% of patients with duodenal ulcer and 60-90% of patients with gastric ulcers. The studies have also demonstrated that removal of the organism by antimicrobial therapy is correlated with the resolution of symptoms and cure of diseases. Patients who present with clinical symptoms relating to the gastrointestinal tract can be diagnosed for H. pylori infection by two methods: 1) Invasive techniques include biopsy followed by culture or histological examination of biopsy specimen or direct detection of urease activity. The cost and discomfort to the patients are very high and biopsy samples are subject to errors related to sampling and interference of contaminated bacteria. 2) Non-invasive techniques include urea breath tests (UBT) and serological methods. The UBT requires a high density and active bacteria and should not be performed until 4 weeks after therapy to allow resisdual bacteria to increase to the detection level. The main limitation of serology test is the inability to distinguish current and past infections.